32 min listen
What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.
What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.
ratings:
Length:
23 minutes
Released:
Mar 21, 2019
Format:
Podcast episode
Description
We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.
Released:
Mar 21, 2019
Format:
Podcast episode
Titles in the series (100)
How Thoughtful Consolidation Can Benefit Ophthalmology by OIS Podcast | Ophthalmology's leading Podcast